Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Study Number: EA9213 (JIT)
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
- Navigator Heather, 309-243-3661 email@example.com
- Hannah, 309-243-3628 firstname.lastname@example.org